-
Mabwell Bioscience Extends Research Partnership with Fudan University Cancer Center
•
Mabwell (Shanghai) Bioscience Co., Ltd., (SHA: 688062) has announced the renewal of its strategic research partnership with Fudan University Shanghai Cancer Center. The collaboration, initiated in July 2021, focuses on advancing research cooperation, nurturing talent, enhancing hospital management, and constructing robust platforms for scientific exchange. The partnership has seen significant…
-
Hengrui Medicine Scores First-Mover Status with FDA Approval for Generic Astagraf XL
•
Jiangsu Hengrui Medicine Co., Ltd (SHA: 600276), a leading pharmaceutical company based in China, has announced that it has received Abbreviated New Drug Application (ANDA) approval from the US Food and Drug Administration (FDA) for its sustained-released generic version of Astagraf XL (tacrolimus), originally developed by Japan-based Astellas. With this…
-
Gilead Increases Stake in Arcus Biosciences and Invests in Anti-TIGIT Program
•
Gilead (NASDAQ: GILD) has strengthened its 2020 collaboration agreement with US-based Arcus Biosciences (NYSE: RCUS) by amending it to accelerate their joint program on the anti-TIGIT monoclonal antibody (mAb) domvanalimab. The amendment includes an additional investment of USD 320 million, which increases Gilead’s ownership stake in Arcus to 33% and…
-
Takeda’s Gammagard Liquid Approved by FDA for Chronic Inflammatory Demyelinating Polyneuropathy
•
The US Food and Drug Administration (FDA) has granted regulatory approval for Takeda’s (TYO: 4502) plasma-derived therapy Gammagard Liquid, a human immune globulin, for use as induction therapy and treatment for chronic inflammatory demyelinating polyneuropathy (CIDP) in adults. This decision is supported by clinical data demonstrating that the intravenous immunoglobulin…
-
Shaanxi Province Unveils Ambitious Three-Year Plan to Boost Traditional Chinese Medicine Industry
•
The provincial government of Shaanxi has unveiled the “Three Year Action Plan for Empowering Shaanxi Province with Traditional Chinese Medicine (TCM) (2024-2026),” with ambitions to position its TCM facilities among the nation’s leaders and to achieve a total industry output value of RMB 100 billion by 2026. The plan outlines…
-
AstraZeneca’s Enhertu Receives Priority Review for Expanded HER2-positive Solid Tumor Indication
•
UK pharmaceutical company AstraZeneca (AZ; NASDAQ: AZN) has announced that an indication extension filing for Enhertu (trastuzumab deruxtecan), submitted in partnership with Japan’s Daiichi Sankyo (TYO: 4568) to the US Food and Drug Administration (FDA), has been granted priority review. The treatment is now under consideration for unresectable or metastatic…
-
MicroPort Scientific Corp. Forecasts 31%-34% Revenue Growth for Subsidiary MicroPort Endovascular in 2023
•
Shanghai-based medical device conglomerate MicroPort Scientific Corp., (HKG: 0853) has issued a revenue and growth forecast for its subsidiary Shanghai MicroPort Endovascular MedTech Co., Ltd (SHA: 688016), in which it holds a 40.32% stake. MicroPort Endovascular is anticipated to achieve revenues within the range of RMB 1.17-1.2 billion (USD 168-238…
-
SANDT Secures Nearly RMB 200 Million to Boost X-ray System Development and Manufacturing
•
SANDT, a Shanghai-based specialist in X-ray systems, has reportedly secured nearly RMB 200 million (USD 28 million) in a recent financing round. The investment was led by Zhongxin Capital, with participation from other undisclosed investors. The funds raised will be allocated towards research and development, as well as the manufacturing…
